Compare BUUU & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUUU | HURA |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.6M | 131.8M |
| IPO Year | 2025 | N/A |
| Metric | BUUU | HURA |
|---|---|---|
| Price | $7.89 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 107.4K | ★ 351.6K |
| Earning Date | 02-20-2026 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $6,328,425.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $149.17 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $3.67 | $0.68 |
| 52 Week High | $20.76 | $5.27 |
| Indicator | BUUU | HURA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 28.40 |
| Support Level | N/A | $0.70 |
| Resistance Level | N/A | $0.78 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 0.42 |
BUUU Group Ltd provides comprehensive meetings, incentives, conferences, and exhibitions (MICE) solutions focused on event management and stage production. Its event management team offers creative planning, project management, and on-site supervision for a wide range of cultural, artistic, recreational, and corporate events, working closely with clients and partners. The stage production team creates immersive event experiences by managing lighting, audio-visual systems, stage performance elements, and venue decorations, overseeing the entire production process. Event management generates the majority of revenue.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.